GLPwatch

The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

NCT05078255 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of long-term activation of GIP and GLP-1 receptors, alone and together, in adults with type 2 diabetes and obesity to measure changes in blood sugar levels using continuous glucose monitoring.

Status Completed The study has finished.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Randomized, triple-blind treatment study
Participants 61 people
Who can join Ages 18–74 · all sexes
Timeline Started 2022-01 · est. completion 2025-01
Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT05078255 ↗

Description as written by the study sponsor.

Due to reports of a severely reduced insulinotropic effect of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) in type 2 diabetes (T2D), GIP has not been considered therapeutically viable in T2D. Recently, however, tirzepatide, a novel dual incretin receptor agonist (activating both the GIP receptor and the glucagon-like peptide 1 (GLP-1) receptor) demonstrated massive improvements in glycaemic control and robust body weight losses; greater than observed with the GLP-1 receptor agonist semaglutide. However, the contribution of GIP receptor activation to these effects remains unknown. The present study will evaluate the glucose-lowering effect of GIP in the context of pharmacological GLP-1 receptor activation in patients with T2D.

Treatments tested

Main thing measuredMean glucose levels (assessed by blinded continuous glucose monitoring (CGM))
SponsorAsger Lund, MD
Conditions studiedType 2 Diabetes, Obesity
GLP-1 drugs —

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05078255 ↗